Summit Therapeutics PLC (SMMT) closed the last trading session at $25.85, gaining 10.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $37.38 indicates a 44.6% upside potential.The average comprises eight short-term price targets ranging from a low of $30 to a high of $44, with a standard deviation of $5.71. While the lowest estimate indicates an increase of 16.1% from the current ...

Shares of Roku (ROKU) have gained 5% over the past four weeks to close the last trading session at $69.01, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $88.87 indicates a potential upside of 28.8%.The mean estimate comprises 26 short-term price targets with a standard deviation of $17.78. While the lowest estimate of $60 indicates a 13.1% decline from the current price level, ...

Core Viewpoint - Adeia (ADEA) shows potential for significant upside, with a mean price target of $17.33 indicating a 37% increase from its current price of $12.65 [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $0.58, suggesting a consensus among analysts [2] - The lowest estimate of $17 indicates a 34.4% increase, while the highest estimate suggests a 42.3% increase to $18 [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about ADEA's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, one estimate has increased, leading to a 1% rise in the Zacks Consensus Estimate [12] - ADEA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, as empirical research shows they rarely indicate actual price movements [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors should treat price targets with skepticism and not rely solely on them for investment decisions [10]

Consensus Cloud Solutions, Inc. (CCSI) closed the last trading session at $21.37, gaining 10.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $27.40 indicates a 28.2% upside potential.The average comprises five short-term price targets ranging from a low of $20 to a high of $37, with a standard deviation of $7.06. While the lowest estimate indicates a decline of 6.4% from the cur ...

Copa Holdings (CPA) closed the last trading session at $106.47, gaining 17.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $152.73 indicates a 43.5% upside potential.The average comprises 11 short-term price targets ranging from a low of $125 to a high of $190, with a standard deviation of $19.78. While the lowest estimate indicates an increase of 17.4% from the current price le ...

Core Viewpoint - Priority Technology (PRTH) shows potential for significant upside, with a mean price target of $12.80 indicating a 67.1% increase from the current price of $7.66 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $2.77, indicating variability among analysts [2] - The lowest estimate of $10 suggests a 30.6% increase, while the highest estimate predicts a surge of 108.9% to $16 [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism regarding PRTH's earnings prospects, with a strong consensus in revising EPS estimates higher [11] - The Zacks Consensus Estimate for the current year has risen by 1.9% over the past month, with one estimate increasing and no negative revisions [12] - PRTH holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13]

Braze, Inc. (BRZE) closed the last trading session at $34.73, gaining 11.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $50.16 indicates a 44.4% upside potential.The mean estimate comprises 19 short-term price targets with a standard deviation of $9.15. While the lowest estimate of $38 indicates a 9.4% increase from the current price level, the most optimistic analyst expects t ...

Core Viewpoint - Kontoor Brands (KTB) has shown a significant price increase of 13.3% over the past four weeks, with a mean price target of $87.83 indicating a potential upside of 26.2% from the current price of $69.62 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $9.22, suggesting variability in analyst predictions. The lowest estimate of $72 indicates a 3.4% increase, while the highest estimate suggests a 43.6% surge to $100 [2] - Analysts' price targets can often mislead investors, as empirical research shows that these targets rarely indicate actual stock price movements [7][10] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Agreement - There is strong agreement among analysts regarding KTB's ability to report better earnings than previously predicted, which supports the expectation of an upside in the stock [4][11] - The Zacks Consensus Estimate for the current year has increased by 2.9% over the past month, with one estimate rising and no negative revisions [12] - KTB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for near-term upside [13]

Group 1 - Immunome, Inc. (IMNM) shares have increased by 1.1% over the past four weeks, closing at $8.49, with a mean price target of $24.50 indicating a potential upside of 188.6% [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $5.76, where the lowest estimate of $20 suggests a 135.6% increase, and the highest estimate predicts a surge of 347.6% to $38 [2] - Analysts show a consensus that IMNM will report better earnings than previously estimated, which strengthens the outlook for the stock [4][11] Group 2 - Over the last 30 days, five earnings estimates for IMNM have been revised upward, resulting in a Zacks Consensus Estimate increase of 17.9% [12] - IMNM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - The correlation between earnings estimate revisions and near-term stock price movements suggests that the positive trend in earnings estimates could lead to stock price increases [11]

Core Viewpoint - Si-Bone (SIBN) shares have increased by 27.6% in the past four weeks, closing at $18.38, with a mean price target of $24.67 indicating a potential upside of 34.2% [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $3.57, where the lowest estimate is $19 (3.4% increase) and the highest is $32 (74.1% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about SIBN's earnings prospects, as indicated by a positive trend in earnings estimate revisions, with five estimates moving higher and no negative revisions in the last 30 days, resulting in a 7.7% increase in the Zacks Consensus Estimate [11][12] - SIBN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]